The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Key takeaways from a session covering updates in ET, PV, prefibrotic MF, and MPN-AP/BP
In this video, Olatoyosi Odenike, MD, University of Chicago, Chicago, IL, highlights the progress made in treating myeloproliferative neoplasms (MPNs), outlining the key takeaways from a session at the 2025 MPN Workshop of the Carolinas, which covered updates in essential thrombocythemia (ET), polycythemia vera (PV), pre-fibrotic myelofibrosis (MF), and accelerated/blast-phase (AP/BP) MPNs. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
A key takeaway is that we have come a long way and we still have further to go. There’s a lot of interesting trials and approaches being investigated in each of these spaces. For ET, for example, I mentioned briefly in the advanced phase MPN context, we are looking at calreticulin-mutated myeloproliferative neoplasms. Those trials are now open also for patients with ET who have a calreticulin mutation where they haven’t otherwise responded to any of the available therapies...
A key takeaway is that we have come a long way and we still have further to go. There’s a lot of interesting trials and approaches being investigated in each of these spaces. For ET, for example, I mentioned briefly in the advanced phase MPN context, we are looking at calreticulin-mutated myeloproliferative neoplasms. Those trials are now open also for patients with ET who have a calreticulin mutation where they haven’t otherwise responded to any of the available therapies.
In polycythemia vera, we have an exciting new class of agents, which are the hepcidin mimetics. And these really allow patients to potentially not have to be phlebotomized for their polycythemia vera. Phlebotomy goes back to way before my time, but it is still how we approach first-line therapy for polycythemia vera. So I’m very excited to have patients who might now benefit from that class of drugs if we’re fortunate enough to have this FDA approved soon, I hope, based on very exciting results using that class of agents.
For advanced-phase MPNs, accelerated and blast phase disease, I already alluded to the number of promising investigational approaches. I’m excited to see how those pan out, particularly using IDH inhibition, LSD1 inhibition, and other epigenetic modulators.
And finally, for prefibrotic myelofibrosis patients, my take-home for that was, you know, the natural history of these diseases is long, but when they occur, particularly in younger individuals, we need to follow them closely and monitor them for, you know, any sort of early signs of evolution to overt myelofibrosis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
